EP4117718A4 - Cellules souches associées à la maladie inflammatoire de l'intestin (ibd), agents ciblant les cellules souches associées à l'ibd et ses utilisations associées - Google Patents
Cellules souches associées à la maladie inflammatoire de l'intestin (ibd), agents ciblant les cellules souches associées à l'ibd et ses utilisations associées Download PDFInfo
- Publication number
- EP4117718A4 EP4117718A4 EP21768000.8A EP21768000A EP4117718A4 EP 4117718 A4 EP4117718 A4 EP 4117718A4 EP 21768000 A EP21768000 A EP 21768000A EP 4117718 A4 EP4117718 A4 EP 4117718A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- stem cells
- agents
- inflammatory bowel
- bowel disease
- uses related
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0679—Cells of the gastro-intestinal tract
- C12N5/068—Stem cells; Progenitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062987022P | 2020-03-09 | 2020-03-09 | |
PCT/US2021/021450 WO2021183474A1 (fr) | 2020-03-09 | 2021-03-09 | Cellules souches associées à la maladie inflammatoire de l'intestin (ibd), agents ciblant les cellules souches associées à l'ibd et ses utilisations associées |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4117718A1 EP4117718A1 (fr) | 2023-01-18 |
EP4117718A4 true EP4117718A4 (fr) | 2024-05-08 |
Family
ID=77671971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21768000.8A Pending EP4117718A4 (fr) | 2020-03-09 | 2021-03-09 | Cellules souches associées à la maladie inflammatoire de l'intestin (ibd), agents ciblant les cellules souches associées à l'ibd et ses utilisations associées |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230149295A1 (fr) |
EP (1) | EP4117718A4 (fr) |
WO (1) | WO2021183474A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113925861A (zh) * | 2021-12-17 | 2022-01-14 | 北京五和博澳药业股份有限公司 | 黄芩黄酮活性成分及其制剂在制备预防和/或治疗炎症风暴药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100162416A1 (en) * | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
US20140255430A1 (en) * | 2010-09-30 | 2014-09-11 | National University Of Singapore | Methods and reagents for detection and treatment of esophageal metaplasia |
US20160022976A1 (en) * | 2002-02-14 | 2016-01-28 | Gholam A. Peyman | Method and composition for hyperthermally treating cells |
US20200054635A1 (en) * | 2017-04-21 | 2020-02-20 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005247369A1 (en) * | 2004-05-10 | 2005-12-08 | Mdrna, Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
WO2006124021A1 (fr) * | 2005-05-12 | 2006-11-23 | Angiotech International Ag | Compositions et methodes de traitement de maladies diverticulaires |
US9114071B2 (en) * | 2007-04-04 | 2015-08-25 | Sigmoid Pharma Limited | Oral pharmaceutical composition |
EP2704799A4 (fr) * | 2011-05-06 | 2014-10-29 | Lankenau Inst Medical Res | Compositions et procédés pour la prévention d'un cancer de l' sophage |
CN103764076B (zh) * | 2011-06-30 | 2017-06-09 | 万能医药公司 | 可生物降解的内置假体及其制造方法 |
CN102335065B (zh) * | 2011-07-28 | 2013-05-08 | 重庆大学 | 带药物缓释功能的植入式视网膜微刺激电极芯片 |
JP6887435B2 (ja) * | 2016-02-08 | 2021-06-16 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 角膜修復のための生体接着剤 |
US20200157495A1 (en) * | 2017-05-05 | 2020-05-21 | Tract Pharmaceuticals, Inc. | Inflammatory bowel disease stem cells, agents which target ibd stem cells, and uses related thereto |
CA3135020A1 (fr) * | 2019-04-26 | 2020-10-29 | University Of Houston System | Methodes et compositions pour traiter une lesion inflammatoire chronique, une metaplasie, une dysplasie et des cancers des tissus epitheliaux |
-
2021
- 2021-03-09 US US17/906,027 patent/US20230149295A1/en active Pending
- 2021-03-09 WO PCT/US2021/021450 patent/WO2021183474A1/fr unknown
- 2021-03-09 EP EP21768000.8A patent/EP4117718A4/fr active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160022976A1 (en) * | 2002-02-14 | 2016-01-28 | Gholam A. Peyman | Method and composition for hyperthermally treating cells |
US20100162416A1 (en) * | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
US20140255430A1 (en) * | 2010-09-30 | 2014-09-11 | National University Of Singapore | Methods and reagents for detection and treatment of esophageal metaplasia |
US20200054635A1 (en) * | 2017-04-21 | 2020-02-20 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
Non-Patent Citations (4)
Title |
---|
DULEBA MARCIN ET AL: "Unlimited expansion of intestinal stem cells from a wide range of ages", INTEGRATIVE MOLECULAR MEDICINE, vol. 6, no. 4, 15 July 2019 (2019-07-15), pages 1 - 5, XP093143659, ISSN: 2056-6360, Retrieved from the Internet <URL:https://dx.doi.org/10.15761/IMM.1000375> DOI: 10.15761/IMM.1000375 * |
See also references of WO2021183474A1 * |
YAGLOM JULIA A. ET AL: "Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations", SCIENTIFIC REPORTS, vol. 8, no. 1, 14 February 2018 (2018-02-14), US, XP093142653, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-017-14900-0.pdf> [retrieved on 20240302], DOI: 10.1038/s41598-017-14900-0 * |
YU LIN ET AL: "Poly(lactic acid-co-glycolic acid)-poly(ethylene glycol)-poly(lactic acid-co-glycolic acid) thermogel as a novel submucosal cushion for endoscopic submucosal dissection", ACTA BIOMATERIALIA, vol. 10, no. 3, 1 March 2014 (2014-03-01), AMSTERDAM, NL, pages 1251 - 1258, XP093143158, ISSN: 1742-7061, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/273258/1-s2.0-S1742706114X00024/1-s2.0-S174270611300603X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEOf//////////wEaCXVzLWVhc3QtMSJGMEQCIAHIlhC4B6jXxeVhwVuwOp1bJxkCdP4pJNBqnb2NNDxqAiAKhQCtcLh7g7AEYtXvmbRhT+KpV+ANXg0eHeu8bguJMSq8BQjw//////////8BEAUaDDA1OTAwMzU0N> [retrieved on 20240312], DOI: 10.1016/j.actbio.2013.12.007 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021183474A1 (fr) | 2021-09-16 |
EP4117718A1 (fr) | 2023-01-18 |
US20230149295A1 (en) | 2023-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3942754A4 (fr) | Routage de pondération | |
EP3638267A4 (fr) | Cellules souches associées à la maladie inflammatoire de l'intestin, agents ciblant lesdites cellules souches et utilisations associées | |
EP3954214A4 (fr) | Compositions biologiques à fonctions multiples | |
WO2008148068A8 (fr) | Vecteurs multicistroniques et procédés pour leur conception | |
BRPI0814651A2 (pt) | Métodos e composições para expansão e implante de células-tronco mesenquimais otimizados. | |
WO2007000668A3 (fr) | Vecteur de genes | |
WO2008152008A3 (fr) | Compositions et méthodes d'utilisation de l'interférence arn pour lutter contre les nématodes | |
EP3917580A4 (fr) | Fixation d'épitope médiée par un peptide phlip® au niveau de surfaces cellulaires | |
EP3789289B8 (fr) | Mécanisme à vilebrequin d'arc boutement double pour volet | |
EP3946182A4 (fr) | Pessaire pour prolapsus de l'organe pelvien | |
EP3908294A4 (fr) | Expansion de cellules modifiées et ses utilisations | |
EP3768262A4 (fr) | Compositions et méthodes pour traiter une maladie inflammatoire de l'intestin et des maladies et des affections provoquées par ou associées à fusobacterium | |
EP4117718A4 (fr) | Cellules souches associées à la maladie inflammatoire de l'intestin (ibd), agents ciblant les cellules souches associées à l'ibd et ses utilisations associées | |
EP4172018A4 (fr) | Prédiction de trajectoire d'agent à l'aide d'emplacements cibles | |
EP4044966A4 (fr) | Prothèse endovasculaire avec conduit interne pouvant être ouvert de manière sélective | |
EP3962955A4 (fr) | Cellules car-t ciblées par un antigène cd19 spécifique | |
EP3458466A4 (fr) | Diagnostic de maladie intestinale inflammatoire basé sur des gènes | |
EP3877328A4 (fr) | Mélanges de dérivés du fullerène, leurs procédés de préparation et utilisations associées | |
EP4035429A4 (fr) | Architectures convergées physiquement sans fil filaires | |
GB202110817D0 (en) | Shape memory alloy actuator | |
EP4006196A4 (fr) | Cible de pulvérisation | |
EP3969596A4 (fr) | Cellules, tissus, organes et/ou animaux ayant un ou plusieurs gènes modifiés pour une survie et/ou une tolérance améliorée à la xénogreffe | |
EP3837361A4 (fr) | Complexe ahr-ror-gamma t utilisable en tant que biomarqueur et cible thérapeutique pour les maladies auto-immunes et les maladies associées à l'il-17a | |
WO2009020343A3 (fr) | Composition et kit diagnostiques du carcinome cellulaire rénal | |
EP4077708A4 (fr) | Procédés et compositions efficaces pour pcr d'amplification cible mulitplex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221004 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240408 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/00 20060101ALI20240402BHEP Ipc: A61P 19/02 20060101ALI20240402BHEP Ipc: A61P 1/04 20060101ALI20240402BHEP Ipc: A61P 1/00 20060101ALI20240402BHEP Ipc: A61K 39/395 20060101ALI20240402BHEP Ipc: A61K 39/00 20060101AFI20240402BHEP |